Clinical Trial Search Results for "TRITON-TIMI 38"

Wiviott, S. D., Antman, E. M., Gibson, C. M., Montalescot, G., Riesmeyer, J., Weerakkody, G., Winters, K. J., Warmke, J. W., McCabe, C. H., Braunwald, E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J. 2006;152(4):627-35. Abstract

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 2007;357(20):2001-15. Abstract

Antman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., Chandna, H., Macias, W., McCabe, C. H., Braunwald, E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol. 2008;51(21):2028-33. Abstract

Murphy, S. A., Antman, E. M., Wiviott, S. D., Weerakkody, G., Morocutti, G., Huber, K., Lopez-Sendon, J., McCabe, C. H., Braunwald, E. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Eur Heart J. 2008;29(20):2473-9. Abstract

Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., McCabe, C. H., Antman, E. M. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation. 2008;118(16):1626-36. Abstract

Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J. P., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., Antman, E. M. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet. 2008;371(9621):1353-63. Abstract

Wiviott, S. D., Braunwald, E., Murphy, S. A., Antman, E. M. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Am J Cardiol. 2008;101(9):1367-70.

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., Sabatine, M. S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation. 2009;119(19):2553-60. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., Sabatine, M. S. Cytochrome p-450 polymorphisms and response to clopidogrel New England journal of medicine. 2009;360(4):354-62. Abstract

Michelson, A. D., Frelinger, A. L., 3rd, Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., Jakubowski, J. A., Li, Y., Murphy, S. A., Qin, J., McCabe, C. H., Antman, E. M., Wiviott, S. D. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial European heart journal. 2009;30(14):1753-63. Abstract

Montalescot, G., Wiviott, S. D., Braunwald, E., Murphy, S. A., Gibson, C. M., McCabe, C. H., Antman, E. M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet. 2009;373(9665):723-31. Abstract

Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., Braunwald, E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation. 2009;119(21):2758-64. Abstract

O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., Shen, L., Mega, J. L., Sabatine, M. S., Wiviott, S. D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet. 2009;374(9694):989-97. Abstract

O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., Penny, W. F., Fridrich, V., McCabe, C. H., Sabatine, M. S., Wiviott, S. D. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis Journal of the American College of Cardiology. 2009;54(8):678-85. Abstract

Pride, Y. B., Wiviott, S. D., Buros, J. L., Zorkun, C., Tariq, M. U., Antman, E. M., Braunwald, E., Gibson, C. M. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy American heart journal. 2009;158(3):e21-6. Abstract

Wrishko, R. E., Ernest, C. S., 2nd, Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J. R., Macias, W. L., Rohatagi, S., Salazar, D. E., Antman, E. M., Wiviott, S. D., Braunwald, E., Ni, L. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 Journal of clinical pharmacology. 2009;49(8):984-98. Abstract

Mahoney, E. M., Wang, K., Arnold, S. V., Proskorovsky, I., Wiviott, S., Antman, E., Braunwald, E., Cohen, D. J. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation. 2010;121(1):71-9. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Walker, J. R., Simon, T., Antman, E. M., Braunwald, E., Sabatine, M. S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet. 2010;376(9749):1312-9. Abstract

Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., Horne, B. D., Hulot, J. S., Kastrati, A., Montalescot, G., Neumann, F. J., Shen, L., Sibbing, D., Steg, P. G., Trenk, D., Wiviott, S. D., Sabatine, M. S. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA. 2010;304(16):1821-30. Abstract

Pride, Y. B., Tung, P., Mohanavelu, S., Zorkun, C., Wiviott, S. D., Antman, E. M., Giugliano, R., Braunwald, E., Gibson, C. M. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy JACC Cardiovascular interventions. 2010;3(8):806-11. Abstract

Wiviott, S. D., Antman, E. M., Braunwald, E. Prasugrel Circulation. 2010;122(4):394-403.

Wiviott, S. D., Antman, E. M., Braunwald, E. Mortality in the TRITON trial: update from the FDA prasugrel action package Am J Cardiol. 2010;106(2):293-4.

Hochholzer, W., Trenk, D., Mega, J. L., Morath, T., Stratz, C., Valina, C. M., O'Donoghue, M. L., Bernlochner, I., Contant, C. F., Guo, J., Sabatine, M. S., Schomig, A., Neumann, F. J., Kastrati, A., Wiviott, S. D., Sibbing, D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy Am Heart J. 2011;162(3):518-26 e5. Abstract

Hochholzer, W., Wiviott, S. D., Antman, E. M., Contant, C. F., Guo, J., Giugliano, R. P., Dalby, A. J., Montalescot, G., Braunwald, E. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) Circulation. 2011;123(23):2681-9. Abstract

Wiviott, S. D., Desai, N., Murphy, S. A., Musumeci, G., Ragosta, M., Antman, E. M., Braunwald, E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies Am J Cardiol. 2011;108(7):905-11. Abstract

Bonaca, M. P., Wiviott, S. D., Braunwald, E., Murphy, S. A., Ruff, C. T., Antman, E. M., Morrow, D. A. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Circulation. 2012;125(4):577-83. Abstract

O'Donoghue, M. L., Vaidya, A., Afsal, R., Alfredsson, J., Boden, W. E., Braunwald, E., Cannon, C. P., Clayton, T. C., de Winter, R. J., Fox, K. A., Lagerqvist, B., McCullough, P. A., Murphy, S. A., Spacek, R., Swahn, E., Windhausen, F., Sabatine, M. S. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials Journal of the American College of Cardiology. 2012;60(2):106-11. Abstract

Ruff, C. T., Giugliano, R. P., Antman, E. M., Murphy, S. A., Lotan, C., Heuer, H., Merkely, B., Baracioli, L., Schersten, F., Seabro-Gomes, R., Braunwald, E., Wiviott, S. D. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world Int J Cardiol. 2012;155(3):424-9. Abstract

Kohli, P., Udell, J. A., Murphy, S. A., Cannon, C. P., Antman, E. M., Braunwald, E., Wiviott, S. D. Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 Study J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Mogabgab, O., Wiviott, S. D., Cannon, C. P., Sloan, S., Sabatine, M. S., Antman, E. M., Braunwald, E., Giugliano, R. P. Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial J Cardiovasc Pharmacol Ther. 2013;NA(NA):NA. Abstract

Ojeifo, O., Wiviott, S. D., Antman, E. M., Murphy, S. A., Udell, J. A., Bates, E. R., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Trial JACC Cardiovasc Interv. 2013;NA(NA):NA. Abstract

Bonaca, M. P., Murphy, S. A., Miller, D., Herrman, J. P., Gottlieb, S., Keltai, M., Menozzi, A., Nicolau, J. C., Widimsky, P., Antman, E. M., Wiviott, S. D. Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry Clin Cardiol. 2014;NA(NA):NA. Abstract